EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brain tumor classification from FFPE samples using nanopore methylation sequencing

Galina Feinberg-Gorenshtein iD, Assaf Grunwald, Carlo Vermeulen, Nurit Gal Mark, Elena Shinderman-Maman, Adva Levy-Barda, Keren Shichrur, Michal Hameiri-Grossman, Orli Michaeli, Shira Amar, Suzanna Fichman, Abraham Natan und 11 weitere

NAR Cancer · 2025

DOI: 10.1093/narcan/zcaf038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Galina Feinberg-Gorenshtein und 22 weiteren Autor:innen. Beteiligte Einrichtung: The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel. Hauptthemen laut MEDLINE: DNA Methylation, Brain Neoplasms, Nanopore Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, European Research Council, Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxford Nanopore Technology (ONT)-based methylation sequencing is emerging as a powerful approach for the rapid and accurate classification of brain tumors, an essential component of precision oncology. However, its broader clinical adoption has been limited by reliance on fresh-frozen (FF) tissue, whereas the vast majority of clinical specimens are formalin-fixed paraffin-embedded (FFPE). In this study, we address this limitation by evaluating the effects of FFPE processing on DNA methylation profiles and introducing a validated protocol for ONT-based classification using DNA extracted directly from pathology-marked regions on stained FFPE slides. This approach enables the targeted selection of tumor-rich areas following histological assessment, thereby improving DNA input quality and tumor content. We demonstrate that even small, low-input samples (≥25 ng) can be successfully classified using this method, with high concordance to final integrated neuropathological diagnoses. Our results show that, despite modest methylation loss associated with formalin fixation, classification performance remains robust. Notably, we identify a correlation between methylation degradation and fixation time, supporting a recommendation to limit formalin exposure to ≤3–4 days when possible. By enabling accurate methylation-based tumor classification from routinely processed, stained FFPE tissue, our protocol integrates seamlessly into existing clinical workflows. This expands the accessibility of ONT-based diagnostics and supports informed, timely treatment decisions—even in cases with minimal tissue availability or urgent clinical need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationBrain NeoplasmsNanopore SequencingHumansParaffin EmbeddingTissue FixationFormaldehyde

Substanzen

Formaldehyde

Autor:innen und Institutionen

  • The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
  • Department of Physical Chemistry, School of Chemistry, Tel Aviv University, P.O. Box 39040, Tel Aviv, Israel.
  • Center for Molecular Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
  • Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center (Beilinson Campus), 39 Jabotinsky Street, Petah Tikva 4941492, Israel.
  • Biobank, Department of Pathology, Rabin Medical Center (Beilinson Hospital), Attn: Biobank, 39 Ze'ev Jabotinsky Street, Petah Tikva 4941492, Israel.
  • Department of Digital Medical Technologies, Holon Institute of Technology, P.O. Box 305, Holon, Israel.

ORCID-Profile: Galina Feinberg-Gorenshtein

Förderung

  • NHGRI NIH HHS
  • European Research Council
  • Israel Science Foundation
  • National Institutes of Health
  • Tel Aviv University
  • Cancer Biology Research Center at Tel Aviv University
  • Nevzlin Family Foundation
  • Israel Cancer Research Fund

Zitieren

APA

Feinberg-Gorenshtein, G., Grunwald, A., Vermeulen, C., Mark, N. G., Shinderman-Maman, E., Levy-Barda, A., Shichrur, K., Hameiri-Grossman, M., Michaeli, O., Amar, S., Fichman, S., Natan, A., Siegal, T., Yust-Katz, S., Weiss, H., Konen, O., Kershenovich, A., Kanner, A. A., de Ridder, J., …, & Ebenstein, Y. (2025). Brain tumor classification from FFPE samples using nanopore methylation sequencing. NAR Cancer. https://doi.org/10.1093/narcan/zcaf038

Vancouver

Feinberg-Gorenshtein G, Grunwald A, Vermeulen C, Mark NG, Shinderman-Maman E, Levy-Barda A, et al. Brain tumor classification from FFPE samples using nanopore methylation sequencing. NAR Cancer. 2025. doi:10.1093/narcan/zcaf038

BibTeX
@article{FeinbergGorenshtein2025,
  author = {Feinberg-Gorenshtein, Galina and Grunwald, Assaf and Vermeulen, Carlo and Mark, Nurit Gal and Shinderman-Maman, Elena and Levy-Barda, Adva and Shichrur, Keren and Hameiri-Grossman, Michal and Michaeli, Orli and Amar, Shira and Fichman, Suzanna and Natan, Abraham and Siegal, Tali and Yust-Katz, Shlomit and Weiss, Hanna and Konen, Osnat and Kershenovich, Amir and Kanner, Andrew A and de Ridder, Jeroen and Toledano, Helen and Izraeli, Shai and Birger, Yehudit and Ebenstein, Yuval},
  title = {Brain tumor classification from FFPE samples using nanopore methylation sequencing},
  journal = {NAR Cancer},
  year = {2025},
  doi = {10.1093/narcan/zcaf038}
}
Kostenlos starten →